Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.

about

Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.

Item

http://www.wikidata.org/entity/Q54863183

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Contemporary Management of Met ...... c and Locoregional Approaches.

@en

Contemporary Management of Met ...... c and Locoregional Approaches.

@nl

type

Item

label

Contemporary Management of Met ...... c and Locoregional Approaches.

@en

Contemporary Management of Met ...... c and Locoregional Approaches.

@nl

prefLabel

Contemporary Management of Met ...... c and Locoregional Approaches.

@en

Contemporary Management of Met ...... c and Locoregional Approaches.

@nl

P1476

Contemporary Management of Met ...... c and Locoregional Approaches.

@en

P2093

Celina Ang

http://www.w3.org/2001/XMLSchema#string

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

P2888

s40487-015-0014-7

P304

1-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40487-015-0014-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert G. Maki

P577

2016-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291014672

http://www.w3.org/2001/XMLSchema#string

P698

28261637

http://www.w3.org/2001/XMLSchema#string

P932

5315077

http://www.w3.org/2001/XMLSchema#string